Immutep ADR Share Price Nasdaq
Stocks
IMMP
US45257L1089
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
01:30:00 30/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 4.710 USD | -3.48% |
|
-16.81% | -91.77% |
| 17/09 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 15/09 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
| Market Cap | 5.01Cr 3.49Cr 3.08Cr 2.92Cr 2.65Cr 4.96Cr 335.36Cr 35Cr 13Cr 171.25Cr 13Cr 13Cr 551.09Cr | P/E 2027 * |
-2x | P/E 2028 * | -3.09x |
|---|---|---|---|---|---|
| Enterprise Value | -44.93L -31.34L -27.66L -26.17L -23.73L -44.5L -30Cr -3.14Cr -1.21Cr -15Cr -1.18Cr -1.15Cr -49Cr | EV / Sales 2027 * |
-1.12x | EV / Sales 2028 * | 5.42x |
| Free-Float |
96.91% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| IMMP | Delayed | |
CBOE
| IMMP | Real-time | |
|
Deutsche Boerse AG
| YP1A | Delayed | |
|
Tradegate
| YP1A | Real-time | |
|
Börse Stuttgart
| YP1A | Delayed |
| 1 day | -3.48% | ||
| 1 week | -16.81% | ||
| Current month | -35.66% | ||
| 1 month | -35.66% | ||
| 3 months | -42.22% | ||
| 6 months | -32.71% | ||
| Current year | -91.77% |
| 1 week | 4.6 |  | 5.7 |
| 1 month | 4.6 | | 8.1 |
| Current year | 4.6 | | 64.6 |
| 1 year | 4.6 | | 70.6 |
| 3 years | 4.6 | | 70.6 |
| 5 years | 4.6 | | 100 |
| 10 years | 4.6 | | 159 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 09/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 01/03/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 09/07/2014 |
Russell Howard
CHM | Chairman | 76 | 17/11/2017 |
Pete Meyers
BRD | Director/Board Member | 57 | 12/02/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.48% | -16.81% | - | - | 3.52Cr | |
| -0.03% | +6.41% | +11.83% | +38.36% | 4.91TCr | |
| -0.73% | -0.41% | +48.84% | +36.72% | 4.46TCr | |
| +1.36% | +6.03% | +343.85% | +638.73% | 4.32TCr | |
| -0.47% | -0.76% | +9.75% | +103.07% | 4.17TCr | |
| +0.34% | -1.38% | +5.53% | +47.36% | 2.99TCr | |
| +1.00% | -1.28% | +24.23% | +156.93% | 1.72TCr | |
| -2.94% | +6.98% | +5.10% | - | 1.54TCr | |
| -3.20% | -2.38% | +25.00% | +43.67% | 1.55TCr | |
| -0.86% | -4.00% | - | - | 1.51TCr | |
| Average | -0.82% | +1.76% | +59.27% | +152.12% | 3.02TCr | |
| Weighted average by Cap. | -0.24% | +2.17% | +74.36% | +166.74% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 40L 27.9L 24.62L 23.3L 21.13L 39.61L 27Cr 2.79Cr 1.08Cr 14Cr 1.05Cr 1.02Cr 44Cr | 30L 20.92L 18.47L 17.47L 15.85L 29.71L 20Cr 2.1Cr 80.78L 10Cr 78.57L 76.86L 33Cr |
| Net income | -2.61Cr -1.82Cr -1.61Cr -1.52Cr -1.38Cr -2.58Cr -174.69Cr -18Cr -7.03Cr -89Cr -6.84Cr -6.69Cr -287.06Cr | -3.05Cr -2.13Cr -1.88Cr -1.77Cr -1.61Cr -3.02Cr -203.96Cr -21Cr -8.21Cr -104.15Cr -7.98Cr -7.81Cr -335.16Cr |
| Net Debt | -5.46Cr -3.81Cr -3.36Cr -3.18Cr -2.88Cr -5.41Cr -365.43Cr -38Cr -15Cr -186.61Cr -14Cr -14Cr -600.51Cr | -3.38Cr -2.36Cr -2.08Cr -1.97Cr -1.79Cr -3.35Cr -226.44Cr -24Cr -9.11Cr -115.63Cr -8.86Cr -8.67Cr -372.11Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | $4.710 | -3.48% | 33,763 |
| 28/26/28 | $4.880 | -7.40% | 49,146 |
| 25/26/25 | $5.270 | +0.57% | 33,255 |
| 24/26/24 | $5.240 | -1.54% | 12,066 |
| 23/26/23 | $5.322 | -6.00% | 37,575 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMM Stock
- IMMP Stock
Select your edition
All financial news and data tailored to specific country editions
